Resurrect Bio Raises $10.3M for Disease-Resistant Crops

Jan de Vries · 2026-05-14

A London-based agricultural biotech startup just scored a major funding round to tackle one of farming's biggest headaches: crop disease. Resurrect Bio has closed its Series A at $10.3 million (€8.8 million), and they've got big plans for that cash. ### The Money Story The round was actually oversubscribed, meaning investors were fighting to get in. That's a good sign. It was led by Corteva through its Corteva Catalyst platform, with help from Calculus Capital, Pymwymic, UKI2S (managed by Future Planet Capital), SynBioVen, and AgFunder. This final close brings Resurrect Bio's total funding to about $12.4 million since it started, including a seed round back in 2023. Not bad for a company that only spun out of The Sainsbury Laboratory in Norwich in 2022.  ### What They're Actually Doing Here's the thing about crop diseases: they're sneaky. Pathogens evolve to weaken a plant's immune system, and that's when things go wrong. Resurrect Bio's approach is pretty clever. Instead of spraying chemicals, they're using gene editing to wake up the crop's own natural defenses. Think of it like this. Your body has an immune system that fights off colds. But what if the cold virus could turn off parts of that system? That's what plant pathogens do. Resurrect Bio's tech basically reboots the plant's immune response, locking the pathogen out. The company has three core platforms they're scaling with this new money: - FloraFold AI: An in silico discovery platform that predicts how plant and pathogen proteins interact - High-throughput functional biology platform: Validates those predictions at scale - Resurrection platform: Reactivates hidden resistance mechanisms already in elite germplasm Together, these tools dramatically compress the timeline from discovery to deployment. That's huge for farmers who need solutions fast. ### Why This Matters Crop disease is a massive problem that doesn't get enough attention. Elizabeth Klein-Edmonds, Investment Director at Calculus Capital, put it well: "Crop disease remains a major and often overlooked challenge in global agriculture." She added that Resurrect Bio's gene-editing platform "offers a promising solution by reducing dependence on chemicals and boosting yields." That's a win-win for everyone. ### What's Next Dr. Cian Duggan, the CEO, says the company is expanding its team and deepening its platforms. They're actively looking for joint development agreements with seed companies and breeders who want durable resistance traits for farmers. In March 2026, they already announced a partnership with Corteva Agriscience to develop disease resistance in corn. That's a big deal. Corn is one of the world's most important crops, and any breakthrough there has massive implications for global food security. The company's founders—Prof. Sophien Kamoun, Prof. Tolga Bozkurt, and Dr. Cian Duggan—aren't messing around. They're on a mission to become the world's leading plant disease resistance company. And with $12.4 million in the bank and a clear plan, they've got a solid shot at it. ### The Bottom Line Resurrect Bio is doing something that actually matters. They're replacing chemical crop protection with a smarter, more sustainable solution. And investors are betting big on that vision. If you're in the seed business or just care about where your food comes from, this is one to watch. The company is ready to engage with seed companies and breeders through additional joint development agreements. They want to bring durable disease-resistance traits to commercial pipelines faster than conventional breeding can achieve. That's the kind of innovation we need more of.